Race to the Bottom? What Pricing Pressure Is Doing to Wound Care

Pricing has become the dominant variable in wound care, and most conversations now start and end there—what fits within the allowable, what can be sourced cheaper, how to make the numbers hold.

Behind that lives a layer of work that determines whether a case holds together once it moves past authorization. Coverage verification, authorization strategy, documentation support, logistics, and access to someone who can step in when something breaks. These intangibles keep cases from turning into problems later.

As pricing compresses, access to that layer becomes less consistent. Verification loses precision, authorization is handled more passively, and documentation support becomes harder to reach. Logistics begin to shift back toward the practice, while the cost of defending an audit remains unchanged even as margins narrow.

What This Looks Like in Practice

A physician recently called about what initially looked like a straightforward Medicare patient. A closer review showed it was a regional Medicare Advantage plan. Authorization was in place, and there was no immediate reason to adjust the clinical plan.

The wound supported full weekly applications. Under normal conditions, that is how the case would have progressed.

Instead, the approach was scaled back. A smaller portion of the wound was treated first to see how the plan would behave once billing began. There was little precedent to rely on, even after checking across multiple contacts.

The first application went through. The plan did not pay.

If the full wound had been treated at the outset, the exposure would have been immediate and significantly larger, and the care plan would have had to be reworked midstream. Starting smaller kept the situation contained and avoided putting the patient in the middle of something that could not be carried through.

That kind of adjustment comes from experience with how these plans behave once claims move past authorization.

There has always been skepticism around field support in wound care, and some of it has been warranted. Higher-margin periods brought in people focused on volume over durability, and much of that has already worked its way out.

What remains is a layer of practical judgment that tends to operate quietly. It shows up when a graft size is adjusted before it creates a billing issue, when a shipment delay is caught early enough to avoid disrupting care, or when a documentation gap is addressed before it turns into a denial. Those moments are not particularly visible on their own, but together they keep cases on track.

Where Pricing Pressure Starts to Show

As that layer thins, those adjustments happen less consistently and more of the responsibility shifts back to the practice.

That is where pricing pressure becomes tangible. Practices take on more of that coordination directly—interpreting how plans behave, managing logistics, and working through denials with less external support. At the same time, the economics become less forgiving. A single application may generate a few hundred dollars, while defending an audit can cost several times that. The exposure remains, and there is less margin to absorb it.

Over time, the structure of the market adjusts.
Support becomes more centralized. Field coverage stretches across larger territories. Response times slow. Lower-volume practices receive less attention. Relationships move from direct access to queue-based support.

That model can function in larger systems with internal resources to absorb the added complexity. It tends to strain smaller, independent practices where fewer people are available to manage the operational side of care.

At the clinic level, the impact is gradual. Coverage nuances are easier to miss when verification is less thorough, and denials take longer to resolve when there is no clear escalation path.

Where This Leads

The clinical value of advanced wound care products has not changed. In the right setting, they remain an important part of treatment.

What has changed is the amount of coordination required to use them consistently within the current reimbursement environment. As that coordination becomes more demanding, physicians become more selective. Decisions start to follow what can be carried through without creating instability around the case.

That shift has consequences. Some patients who could benefit from advanced therapies may not receive them because the pathway to deliver them reliably has become harder to manage.

Lower pricing in wound care doesn’t reduce cost. It transfers responsibility and creates a more self-managed care system, which introduces greater risk for physicians.

That is where Bionavix fits—helping practices align coverage behavior, documentation, and case strategy before risk builds and while decisions can still be adjusted. We encourage you to reach out if we can be of help.